Strides Pharma Science Posts 82% Profit Surge in Q2 FY26
Published on: Oct. 31, 2025, 2:13 p.m. | Source: Devdiscourse
Strides Pharma Science Ltd reported a significant 82% increase in consolidated net profit for Q2 FY26, reaching Rs 131.52 crore. This growth is attributed to strong revenue from 'other regulated markets' and reduced expenses, with significant performances in the US and emerging markets such as Africa, LATAM, MENA, and APAC.
